AR035203A1 - DERIVATIVES OF PROPIONIC ACID, A PROCEDURE FOR ITS PREPARATION, MEDICATIONS, PROCEDURE FOR THE PREPARATION OF MEDICINES, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES - Google Patents
DERIVATIVES OF PROPIONIC ACID, A PROCEDURE FOR ITS PREPARATION, MEDICATIONS, PROCEDURE FOR THE PREPARATION OF MEDICINES, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINESInfo
- Publication number
- AR035203A1 AR035203A1 ARP010104593A ARP010104593A AR035203A1 AR 035203 A1 AR035203 A1 AR 035203A1 AR P010104593 A ARP010104593 A AR P010104593A AR P010104593 A ARP010104593 A AR P010104593A AR 035203 A1 AR035203 A1 AR 035203A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- alkoxy
- hydrogen
- derivatives
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 abstract 1
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Derivados del ácido propiónico, que comprenden compuestos de la fórmula general (1) en la que: A representa un enlace o un grupo -CH2- ó -CH2-CH2-; X representa O, S ó CH2; R1, R2 y R3 son iguales o distintos y representan independientemente unos de otros, hidrógeno, alquilo C1-6, cicloalquilo C3-7, hidroxilo, alcoxi C1-6, ariloxi C6-10, halógeno, trifluormetilo, trifluormetoxi, alquilaminosulfonilo C1-6, nitro o ciano, o R1 y R2 están unidos a dos átomos de C adyacentes y junto con estos forman un anillo ciclohexano o benceno fusionado, estando el último opcionalmente substituido con un grupo alquilsulfonilmetilo C1-4, y R3 tiene el significado anteriormente indicado; R4 representa hidrógeno o alquilo C1-4; R5 y R6 significan hidrógeno o junto con el átomo de C al que están unidos forman un grupo carbonilo; R7 representa hidrógeno, alquilo C1-6, fenilo o bencilo, pudiendo estar los anillos aromáticos indicados substituidos a su vez respectivamente de 1 a 3 veces por substituyentes iguales o distintos del grupo que consiste de alquilo C1-6, alcoxi C1-6, hidroxilo o halógeno; R8 representa hidrógeno, arilo C6-10 o alquilo C1-4, que a su vez puede estar substituido con hidroxilo, trifluormetoxi, alcoxi C1-4 o fenoxi, que a su vez están substituidos opcionalmente de 1 a 2 veces con trifluormetilo, o con arilo C6-10 o heteroarilo de 5 ó 6 miembros con hasta 3 heteroátomos del grupo N, O y S, pudiendo estar todos los anillos de arilo y heteroarilo indicados substituidos a su vez respectivamente de 1 a 3 veces por substituyentes iguales o distintos del grupo que consiste de halógeno, hidroxilo, alquilo C1-6, alcoxi C1-6, trifluormetilo, trifluormetoxi, ciano, nitro y amino; R9 y R10 son iguales o distintos e independientemente uno de otro representan hidrógeno, alquilo C1-6, alcoxi C1-6, trifluormetilo, trifluormetoxi o halógeno; R11 y R12 son iguales o distintos e independientemente uno de otro representan hidrógeno o alquilo C1-6 o junto con el átomo de C al que están unidos forman un anillo de cicloalquilo C4-7; y R13 representa hidrógeno o un grupo hidrolizable que puede degradarse al correspondiente ácido carboxílico; así como sus sales, hidratos y solvatos farmacéuticamente aceptables; un procedimiento para su preparación, medicamentos, procedimiento para la preparación de medicamentos y el uso de dichos derivados para la manufactura de medicamentos para la profilaxis y tratamiento de enfermedades, como la arteriosclerosis y como agonistas del receptor activado del proliferador de peroxisoma, potentes activadores de PPAR-alfa para el tratamiento de, por ejemplo, la enfermedad coronaria. Compuestos que comprenden la fórmula (2) en la que A, X, R7, R8, R9, R10, R11 y R12 tienen el significado indicado anteriormente; y T representa bencilo, alquilo C1-6 un polímero soporte adecuado para la síntesis en fase sólida.Derivatives of propionic acid, comprising compounds of the general formula (1) in which: A represents a bond or a group -CH2- or -CH2-CH2-; X represents O, S or CH2; R1, R2 and R3 are the same or different and independently represent each other, hydrogen, C1-6 alkyl, C3-7 cycloalkyl, hydroxyl, C1-6 alkoxy, C6-10 aryloxy, halogen, trifluoromethyl, trifluoromethoxy, C1-6 alkylaminosulfonyl , nitro or cyano, or R1 and R2 are attached to two adjacent C atoms and together with these form a fused cyclohexane or benzene ring, the latter being optionally substituted with a C1-4 alkylsulfonylmethyl group, and R3 has the meaning indicated above; R4 represents hydrogen or C1-4 alkyl; R5 and R6 mean hydrogen or together with the C atom to which they are attached form a carbonyl group; R7 represents hydrogen, C1-6 alkyl, phenyl or benzyl, the indicated aromatic rings may be substituted in turn respectively 1 to 3 times by substituents the same or different from the group consisting of C1-6 alkyl, C1-6 alkoxy, hydroxyl or halogen; R8 represents hydrogen, C6-10 aryl or C1-4 alkyl, which in turn can be substituted with hydroxyl, trifluoromethoxy, C1-4 alkoxy or phenoxy, which in turn are optionally substituted 1 to 2 times with trifluoromethyl, or with C6-10 aryl or 5- or 6-membered heteroaryl with up to 3 heteroatoms of the N, O and S group, all indicated aryl and heteroaryl rings being substituted in turn respectively 1 to 3 times by substituents the same or different from the group consisting of halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; R9 and R10 are the same or different and independently of each other represent hydrogen, C1-6 alkyl, C1-6 alkoxy, trifluoromethyl, trifluoromethoxy or halogen; R11 and R12 are the same or different and independently of each other represent hydrogen or C1-6 alkyl or together with the C atom to which they are attached form a C4-7 cycloalkyl ring; and R13 represents hydrogen or a hydrolysable group that can be degraded to the corresponding carboxylic acid; as well as its pharmaceutically acceptable salts, hydrates and solvates; a procedure for its preparation, medicaments, procedure for the preparation of medicaments and the use of said derivatives for the manufacture of medicaments for the prophylaxis and treatment of diseases, such as arteriosclerosis and as agonists of the peroxisome proliferator activated receptor, potent activators of PPAR-alpha for the treatment of, for example, coronary heart disease. Compounds comprising the formula (2) in which A, X, R7, R8, R9, R10, R11 and R12 have the meaning indicated above; and T represents benzyl, C1-6 alkyl a support polymer suitable for solid phase synthesis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10049208 | 2000-10-05 | ||
| DE10124905A DE10124905A1 (en) | 2000-10-05 | 2001-05-22 | propionic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035203A1 true AR035203A1 (en) | 2004-05-05 |
Family
ID=7658699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104593A AR035203A1 (en) | 2000-10-05 | 2001-09-28 | DERIVATIVES OF PROPIONIC ACID, A PROCEDURE FOR ITS PREPARATION, MEDICATIONS, PROCEDURE FOR THE PREPARATION OF MEDICINES, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES |
Country Status (9)
| Country | Link |
|---|---|
| KR (1) | KR20030059175A (en) |
| AR (1) | AR035203A1 (en) |
| DE (1) | DE10124905A1 (en) |
| DO (1) | DOP2001000260A (en) |
| EC (1) | ECSP034536A (en) |
| GT (1) | GT200100198A (en) |
| PE (1) | PE20020475A1 (en) |
| SV (1) | SV2002000677A (en) |
| ZA (1) | ZA200302610B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004247355A1 (en) * | 2003-06-06 | 2004-12-23 | F. Hoffmann-La Roche Ag | Aniline derivatives |
| KR100699928B1 (en) * | 2004-10-05 | 2007-03-26 | 재단법인서울대학교산학협력재단 | Method for preparing intermediates for the preparation of peroxysomal proliferator activated receptor alpha ligands |
-
2001
- 2001-05-22 DE DE10124905A patent/DE10124905A1/en not_active Withdrawn
- 2001-09-24 KR KR10-2003-7004828A patent/KR20030059175A/en not_active Withdrawn
- 2001-09-28 AR ARP010104593A patent/AR035203A1/en not_active Application Discontinuation
- 2001-10-01 GT GT200100198A patent/GT200100198A/en unknown
- 2001-10-04 PE PE2001000987A patent/PE20020475A1/en not_active Application Discontinuation
- 2001-10-04 DO DO2001000260A patent/DOP2001000260A/en unknown
- 2001-10-04 SV SV2001000677A patent/SV2002000677A/en unknown
-
2003
- 2003-04-03 EC EC2003004536A patent/ECSP034536A/en unknown
- 2003-04-03 ZA ZA200302610A patent/ZA200302610B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE10124905A1 (en) | 2002-04-11 |
| ZA200302610B (en) | 2004-04-05 |
| ECSP034536A (en) | 2003-05-26 |
| GT200100198A (en) | 2002-06-25 |
| PE20020475A1 (en) | 2002-06-08 |
| KR20030059175A (en) | 2003-07-07 |
| SV2002000677A (en) | 2002-12-02 |
| DOP2001000260A (en) | 2002-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040352A1 (en) | INDOLINFENYL SULFONAMIDE DERIVATIVES | |
| AR037489A1 (en) | REPLACED KINOLINS AND PROCESS FOR PREPARATION | |
| AR062270A1 (en) | HETEROARILO COMPOUNDS INHIBITORS OF ACTIVATION ENZYMES E1, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES IN DISORDERS ASSOCIATED WITH CELL PROLIFERATION, SUCH AS CANCERES AND INFLAMMATORY DISORDERS. | |
| AR053415A1 (en) | DIPEPTIDIL PEPTIDASA IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF COMPOUNDS AND COMPOSITION | |
| AR061815A1 (en) | OXO-PROLINAMIDE COMPOSITE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
| JPWO2003093238A1 (en) | Quinoline and quinazoline derivatives that inhibit macrophage colony-stimulating factor receptor autophosphorylation | |
| AR038686A1 (en) | FORMULATIONS OF ANDROSTAN DERIVATIVES AND AGONISTS OF THE BETA 2 ANTIINFLAMATORY ADRENORECEPTOR | |
| AR102722A2 (en) | A PIRAZOLO-QUINAZOLINE DERIVATIVE, ITS USE, A PROCEDURE TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, COMPOUNDS USED IN THEIR PREPARATION, A LIBRARY OF TWO OR MORE COMPOUNDS, AND A PRODUCT OR KIT | |
| AR029717A1 (en) | DERIVATIVES OF THE PRO-PHARMACO OF 4-PHENYL-PYRIDINE | |
| CO5580820A2 (en) | NEW ACID DERIVATIVES (2S) -3- (4- {2- [AMINO] -2-OXOETOXI} PHENYL) -2-ETOXIPROPANOIC PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR033306A1 (en) | COMPOUNDS | |
| AR083872A1 (en) | CARBAMOIL-CICLOALQUIL-ACETICO ACID DERIVATIVES REPLACED AS NEP INHIBITORS | |
| SE9702799D0 (en) | New compounds | |
| RU2001123126A (en) | Derivatives of pyridopyranoazepines, their preparation and therapeutic use | |
| AR046793A1 (en) | DERIVADOS DE PIRAZOL, ANTAGONISTS OF THE RECEIVER OF OREXINA | |
| AR072793A1 (en) | ARIL ISOXAZOL COMPOUNDS WITH ANTITUMURAL ACTIVITIES | |
| CA3098219C (en) | A 10h-phenothiazine ferroptosis inhibitor as well as the preparative method and the use thereof | |
| AR040315A1 (en) | ARIL AND HETEROARILCARBONILPIPERAZINAS AND ITS USE FOR THE TREATMENT OF BENIGN AND MALIGNAL TUMOR DISEASES | |
| AR052549A1 (en) | DERIVATIVES OF 2,3,4,9-TETRAHIDRO-1H-CARBAZOL AS AN ANTHOGONIST OF THE CRTH2 RECEIVER | |
| AR041079A1 (en) | DERIVATIVES OF 2-ARILTIAZOL AS AGONISTS OF ACTIVATED RECEPTORS PROLIFERATORS OF PEROXISOMS ALFA AND GAMMA (PPAR ALFA AND GAMMA) | |
| AR037507A1 (en) | DERIVATIVES OF SUBSTITUTED ACETIC ACID, A PROCEDURE FOR THEIR PREPARATION, MEDICATIONS, A PROCEDURE FOR THEIR PREPARATION, THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES | |
| AR010899A1 (en) | OXAZOLIDINONES, A PROCEDURE FOR THEIR PREPARATION, THE USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, MEDICINES AND PREPARATIONS THAT CONTAIN THEM AND A PROCEDURE TO OBTAIN THESE PHARMACEUTICAL PREPARATIONS. | |
| UY28688A1 (en) | AMIDA DERIVATIVES | |
| AR035203A1 (en) | DERIVATIVES OF PROPIONIC ACID, A PROCEDURE FOR ITS PREPARATION, MEDICATIONS, PROCEDURE FOR THE PREPARATION OF MEDICINES, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES | |
| AR051295A1 (en) | DERIVATIVES OF PYRIMIDINE AND ITS USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |